Remove Allergies Remove Cardiology Remove Medicine Remove Research
article thumbnail

Improving European healthcare through cell-based interceptive medicine

Scienmag

Credit: Felix Petermann, MDC Hundreds of innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare.

article thumbnail

Velocity Expands to 17 Sites in Europe

Velocity Clinical Research

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New theory suggests blood immune and clotting components could contribute to psychosis

Scienmag

The article, a joint collaborative effort by researchers at RCSI University of Medicine and Health Sciences, Cardiff University and the UCD Conway Institute, is published in Molecular Psychiatry. […].

article thumbnail

Octapharma presents research on congenital & acquired bleeding disorders at ASH Meeting

Scienmag

Research evaluates use of fibryga®, Octaplas™, and Octaplex® as investigational therapies PARAMUS, N.J.

article thumbnail

Disrupted medical conferences: Lessons learnt

pharmaphorum

Major societies such as the European Society of cardiology (ESC) reported a 177% increase in attendees for its 2020 annual congress : 77,350 virtual attendees (logged-on) 2020 cf 27,946 physical attendees 2019. One important caveat here is that delegate registration fees were waived. Figure 1 What doctors say about virtual events . .

Doctors 105
article thumbnail

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered

Scienmag

Researchers at the University of Toronto have found first evidence that neutrophil immune cell activity is the missing link connecting periodontal disease with heart disease, cancer, and other inflammatory conditions Credit: Noah Fine (TORONTO, ON) Oct.

article thumbnail

Existing heart drugs may help cancer patients respond better to PD(L)1 immunotherapy

Scienmag

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73